Navigation Links
Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod)

Investigational Drug Being Pursued for the Treatment of Ischemic Stroke

GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical development of their investigational drug, Viprinex (ancrod), for the treatment of acute ischemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. Viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper.

"The ancrod data presented this week in Glasgow draws positive conclusions that support a new dosing regimen for ancrod and revised inclusion/exclusion criteria for the current clinical trials," said David Sherman, MD, University of Texas Health Science Center at San Antonio. "The reanalysis enables us to see that ancrod may be safe and effective when administered to patients within six hours of stroke onset. With so few treatments currently available to stroke patients, we look forward to the results of the international phase 3 trials. We hope the phase 3 results provide evidence of definitive safety and efficacy of ancrod in ischemic stroke in the six-hour time window."

    Viprinex(TM)-related sessions at the 2007 European Stroke Congress are:

    -- Poster Session II P 29: Ancrod in a Six Hour Time Window? Evidence For

       and Against Efficacy  by D.G.Sherman University of Texas Health Science

       Center at San Antonio, USA Thursday,  31 May 2007 13:00 to 14:00 GMT

    -- Ongoing Trials Abstract #19: Ancrod Stroke Program (ASP): Two Phase 3

       International, Multi-Center, Randomized, Double-Blind,

       Placebo-Controlled Trials of Ancrod in Acute Ischaemic Stroke by David

       E. Levy, MD (Neurobiological Technologies)

NTI is moving forward with two international, randomized, double-blind, placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
9. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
10. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
11. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
Post Your Comments:
(Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "The Future of ... As they are in a desperate need ... and low cost, drug companies have been increasingly ... enhance their productivity while constantly streamlining their internal ...
(Date:6/3/2015)... 3, 2015  Varian Medical Systems (NYSE: VAR ), world ... cancer, is expanding in the Middle East ... Saudi Arabia . Varian Medical Systems Arabia, the ... was officially launched today at a ceremony attended by local ... "This move represents the next step in our commitment ...
(Date:6/3/2015)... June 02, 2015 Research and Markets ... the "2015 Strategies in the US Tumor ... Highlights of the Report Include ... tumor marker testing market. , Major issues ... as key economic, regulatory, demographic, social and technological ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2
... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
(Date:6/3/2015)... On the heels of a report predicting ... ( click here to review news coverage about the ... has the talent to become a world-leading center of ... other biological data are collected and analyzed to help scientists ... the elements of a perfect storm for bioinformatics leadership,” said ...
(Date:6/3/2015)... Dr. Steven Reisman, a nationally recognized cardiologist ... http://www.newyorkcardiac.com ) located in NYC, announced today the expansion of ... In most cases, depending on the level of care a ... they will be seen by a cardiologist that same day. ... is to ensure that people who have an urgent need ...
(Date:6/3/2015)... 2015 Array Health , a ... announced that CEO Jonathan Rickert will present at ... June 4, 2015. The session will address the how ... traditional business models in health care, and why they ... Digital Transformation and the Health Care Enterprise: Driving ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 Justina ... Global Inspire Award at DIA’s upcoming Annual Meeting. DIA’s ... for their leadership, level of excellence, and commitment to ... will receive the Excellence in Service Award that recognizes ... service as a DIA volunteer and who has contributed ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3
... Eric Artz and team from the Institute of Tropical Medicine ... AIDS, in which they have said that the HIV virus ... is now more sensitive to anti-retroviral drugs compared to the ... the HIV samples collected in between 1986-89 with the samples ...
... disease may not require blood transfusion as a ... form of severe thalassaemia in many Asian// countries—can ... a research letter published online in the September ... the finding has important implications for supplies of ...
... single protein has helped bald mice to get fur on ... balding men., ,Catherine C. Thompson and colleagues at Johns ... known as Hairless, which encodes a protein that is essential ... with mutations in the Hairless gene, hair growth is initially ...
... ban the Environmental Protection Agency (EPA) from using human ... Lawmakers on Capitol Hill will soon decide whether to ... use of studies that expose participants to pesticides. In ... have their pesticides approved by the agency for marketing. ...
... some people vulnerable to suffer from the dreaded disease ... diagnose the risk//. ,According to the most complete ... the researchers from Vanderbilt University in Nashville, Tennessee at ... in San Diego, a cluster of genes on chromosome ...
... a limit to how tiny gadgets, devices and machines ... from an experiment performed by a University of Arizona// ... and assistant professor of physics Alexander D. Cronin. ... can come to a surface before the atoms' wavelengths ...
Cached Medicine News:Health News:US Senate Votes against Testing of Pesticide on Humans 2Health News:Nanotechnologists Specify Limitation For Devising Small Machines 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: